title: Rosuvastatin, sildenafil and their combination in monocrotaline-induced pulmonary hypertension in rat.
abstract: There is considerable interest in the pleiotropic effects of statins and their potential role in the treatment of pulmonary hypertension. Previous experimental findings indicate that a combination of lipophilic statins with phosphodiesterase type-5 inhibitor, sildenafil, can offer preventive effects on rat monocrotaline-induced pulmonary hypertension. The present study is aimed to assess whether therapeutic regimen provides any benefits. Seven days after pulmonary hypertension induction, hydrophilic rosuvastatin and sildenafil were given for 14 days to male Wistar outbred rats. Right ventricular pressure, right ventricle mass and three biomarkers were evaluated after 21 days: brain natriuretic peptide, high-density lipoprotein cholesterol and vascular endothelial growth factor. The present study demonstrates that administration of hydrophilic statin with sildenafil results in reduction of pulmonary vascular remodeling and right ventricular pressure. The results of biochemical measurements may suggest that statins play a positive role in right ventricle function or the process of angiogenesis in pulmonary hypertension development.
authors.forename: Magdalena
authors.initials: M
authors.lastname: Jasińska-Stroschein
authors.forename: Jacek
authors.initials: J
authors.lastname: Owczarek
authors.forename: Anna
authors.initials: A
authors.lastname: Wesołowska
authors.forename: Daria
authors.initials: D
authors.lastname: Orszulak-Michalak
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D062186:Arterial Pressure / Q000187:drug effects*; D015415:Biomarkers / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D005464:Fluorobenzenes / Q000494:pharmacology*; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D006976:Hypertension, Pulmonary / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D017380:Hypertrophy, Right Ventricular / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D016686:Monocrotaline; D020097:Natriuretic Peptide, Brain / Q000097:blood; D058986:Phosphodiesterase 5 Inhibitors / Q000494:pharmacology*; D010879:Piperazines / Q000494:pharmacology*; D011651:Pulmonary Artery / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D011687:Purines / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology*; D017208:Rats, Wistar; D000068718:Rosuvastatin Calcium; D000068677:Sildenafil Citrate; D013449:Sulfonamides / Q000494:pharmacology*; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000097:blood; D066253:Vascular Remodeling / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology*; D016278:Ventricular Function, Right / Q000187:drug effects; D017725:Ventricular Pressure / Q000187:drug effects
chemical_list: D000959:Antihypertensive Agents; D015415:Biomarkers; D008076:Cholesterol, HDL; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D058986:Phosphodiesterase 5 Inhibitors; D010879:Piperazines; D011687:Purines; D011743:Pyrimidines; D013449:Sulfonamides; D042461:Vascular Endothelial Growth Factor A; D014665:Vasodilator Agents; C467498:vascular endothelial growth factor A, rat; D020097:Natriuretic Peptide, Brain; D016686:Monocrotaline; D000068718:Rosuvastatin Calcium; D000068677:Sildenafil Citrate